Ma et al. demonstrated that the increased activation of the RAS pathway as a result of protein kinase c (PKC) overexpression led to BCR::ABL1-independent imatinib resistance in K562 cells, as well as in patient-derived CML leukaemic stem cells [58]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.